Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$49.82

-5.615 (-10.13%)

, MRK

Merck

$63.85

1.075 (1.71%)

15:09
10/10/16
10/10
15:09
10/10/16
15:09

Opdivo trial results may hang on Bristol-Myers shares, WSJ says

Bristol-Myers Squibb's (BMY) disappointing Opdivo trial results may continue to weigh on the shares, Charley Grant writes in the Wall Street Journal's Heard on the Street column. Grant noted that Merck (MRK) presented strong lung cancer data with its Keytruda treatment at the same meeting as Bristol-Myers and may be able to fetch outsized gains. Though Opdivo has outsold Keytruda so far, Bristol-Myers will have a difficult time meeting its growth targets if the lung cancer market slips away, the column says. Reference Link

BMY

Bristol-Myers

$49.82

-5.615 (-10.13%)

MRK

Merck

$63.85

1.075 (1.71%)

  • 25

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

BMY Bristol-Myers
$49.82

-5.615 (-10.13%)

09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
MRK Merck
$63.85

1.075 (1.71%)

10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

UTX

United Technologies

$112.09

-0.57 (-0.51%)

18:32
02/23/17
02/23
18:32
02/23/17
18:32
Hot Stocks
Carrier expands air conditioner, heat pump recall »

United Technologies'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

BREW

Craft Brew

$15.60

-0.25 (-1.58%)

, BUD

AB InBev

$108.76

-0.4 (-0.37%)

18:17
02/23/17
02/23
18:17
02/23/17
18:17
Hot Stocks
Craft Brew reschedules Q4 report to allow additional time for audit »

Craft Brew Alliance…

BREW

Craft Brew

$15.60

-0.25 (-1.58%)

BUD

AB InBev

$108.76

-0.4 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

GLPG

Galapagos NV

$69.96

0.3 (0.43%)

18:17
02/23/17
02/23
18:17
02/23/17
18:17
Hot Stocks
Galapagos doses first healthy volunteer with CF combo GLPG2222, GLPG2451 »

Galapagos announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

RH

Restoration Hardware

$25.19

-0.82 (-3.15%)

, SENS

Senseonics

18:15
02/23/17
02/23
18:15
02/23/17
18:15
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: RH…

RH

Restoration Hardware

$25.19

-0.82 (-3.15%)

SENS

Senseonics

OLED

Universal Display

$67.45

-3.8 (-5.33%)

JWN

Nordstrom

$43.94

-1.41 (-3.11%)

EBS

Emergent BioSolutions

$29.78

-0.14 (-0.47%)

STMP

Stamps.com

$133.75

-0.7 (-0.52%)

MELI

MercadoLibre

$199.82

-0.59 (-0.29%)

BIDU

Baidu

$184.64

-1.37 (-0.74%)

HLF

Herbalife

$59.40

-1.34 (-2.21%)

GPS

Gap

$23.97

-0.9 (-3.62%)

AXDX

Accelerate Diagnostics

$24.75

0.3 (1.23%)

INCY

Incyte

$121.95

0.59 (0.49%)

DDS

Dillard's

$54.68

-0.56 (-1.01%)

NUS

Nu Skin

$47.22

-0.51 (-1.07%)

CONE

CyrusOne

$47.65

-0.08 (-0.17%)

CXW

CoreCivic

$34.00

-0.5 (-1.45%)

GEO

Geo Group

$47.37

-0.38 (-0.80%)

SRPT

Sarepta

$30.15

-0.23 (-0.76%)

ACIA

Acacia Communications

$63.43

1.21 (1.94%)

ZOES

Zoe's Kitchen

$22.46

-0.34 (-1.49%)

ACHC

Acadia

$43.24

0.6 (1.41%)

BGS

B&G Foods

$46.90

-0.65 (-1.37%)

SPLK

Splunk

$64.90

-0.08 (-0.12%)

HPE

HP Enterprise

$24.66

-0.12 (-0.48%)

ACHN

Achillion

$4.24

0.04 (0.95%)

PFGC

Performance Food Group

$24.35

0.4 (1.67%)

NAO

Nordic American Offshore

$2.05

-0.05 (-2.38%)

CELG

Celgene

$119.46

0.19 (0.16%)

HCLP

Hi-Crush Partners

$20.55

-1.4 (-6.38%)

SWN

Southwestern Energy

$8.35

-0.22 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 24

    Feb

  • 24

    Feb

  • 24

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 03

    Mar

  • 06

    Mar

  • 06

    Mar

  • 14

    Mar

  • 19

    Mar

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

  • 28

    Mar

  • 01

    Apr

  • 04

    Apr

  • 05

    Apr

  • 19

    Apr

  • 24

    Feb

  • 24

    Feb

  • 24

    Feb

COF

Capital One

$93.41

0.52 (0.56%)

18:11
02/23/17
02/23
18:11
02/23/17
18:11
Hot Stocks
Capital One: DOJ, Treasury, New York probing anti-money laundering program »

Capital One disclosed in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

XOM

Exxon Mobil

$81.78

0.85 (1.05%)

18:07
02/23/17
02/23
18:07
02/23/17
18:07
Hot Stocks
New Exxon Mobil CEO: 'Climate risks warrant action' »

New Exxon Mobil CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNT

Alliant Energy

$39.11

0.46 (1.19%)

18:04
02/23/17
02/23
18:04
02/23/17
18:04
Earnings
Alliant Energy sees FY17 EPS $1.92-$2.06, consensus $2.00 

Sees FY17 CapEx $1.4B.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 28

    Feb

LNT

Alliant Energy

$39.11

0.46 (1.19%)

18:02
02/23/17
02/23
18:02
02/23/17
18:02
Earnings
Alliant Energy reports Q4 EPS 28c, consensus 28c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 28

    Feb

STZ

Constellation Brands

$153.60

-6.6 (-4.12%)

17:57
02/23/17
02/23
17:57
02/23/17
17:57
Hot Stocks
Constellation Brands says 'ready to act' in any border tax situation »

Sees over $1B in free…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CONE

CyrusOne

$47.65

-0.08 (-0.17%)

, CLC

Clarcor

$82.96

-0.02 (-0.02%)

17:53
02/23/17
02/23
17:53
02/23/17
17:53
Hot Stocks
CyrusOne to replace Clarcor in S&P 400 as of 3/1 open »

S&P 500 constituent…

CONE

CyrusOne

$47.65

-0.08 (-0.17%)

CLC

Clarcor

$82.96

-0.02 (-0.02%)

PH

Parker-Hannifin

$153.70

-2.16 (-1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 06

    Mar

DDS

Dillard's

$54.68

-0.56 (-1.01%)

, ISIL

Intersil

17:52
02/23/17
02/23
17:52
02/23/17
17:52
Hot Stocks
Dillard's to replace Intersil in S&P 400 as of 2/28 open »

Renesas Electronics Corp.…

DDS

Dillard's

$54.68

-0.56 (-1.01%)

ISIL

Intersil

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUS

Nu Skin

$47.22

-0.51 (-1.07%)

, EQY

Equity One

$31.91

0.39 (1.24%)

17:50
02/23/17
02/23
17:50
02/23/17
17:50
Hot Stocks
Breaking Hot Stocks news story on Nu Skin, Equity One »

Nu Skin to replace Equity…

NUS

Nu Skin

$47.22

-0.51 (-1.07%)

EQY

Equity One

$31.91

0.39 (1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

ENDP

Endo

$13.39

0.5 (3.88%)

, REG

Regency Centers

$70.95

0.94 (1.34%)

17:49
02/23/17
02/23
17:49
02/23/17
17:49
Hot Stocks
Breaking Hot Stocks news story on Endo, Regency Centers »

Endo to replace Regency…

ENDP

Endo

$13.39

0.5 (3.88%)

REG

Regency Centers

$70.95

0.94 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 28

    Feb

  • 13

    Mar

  • 14

    Mar

REG

Regency Centers

$70.95

0.94 (1.34%)

, ENDP

Endo

$13.39

0.5 (3.88%)

17:48
02/23/17
02/23
17:48
02/23/17
17:48
Hot Stocks
Regency Centers to replace Endo in S&P 500 as of 3/2 open »

Regency Centers (REG) is…

REG

Regency Centers

$70.95

0.94 (1.34%)

ENDP

Endo

$13.39

0.5 (3.88%)

EQY

Equity One

$31.91

0.39 (1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 28

    Feb

  • 13

    Mar

  • 14

    Mar

PBI

Pitney Bowes

$13.81

-0.02 (-0.14%)

, CBOE

CBOE Holdings

$80.26

-0.28 (-0.35%)

17:46
02/23/17
02/23
17:46
02/23/17
17:46
Hot Stocks
Breaking Hot Stocks news story on Pitney Bowes, CBOE Holdings »

Pitney Bowes to replace…

PBI

Pitney Bowes

$13.81

-0.02 (-0.14%)

CBOE

CBOE Holdings

$80.26

-0.28 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

CBOE

CBOE Holdings

$80.26

-0.28 (-0.35%)

, PBI

Pitney Bowes

$13.81

-0.02 (-0.14%)

17:45
02/23/17
02/23
17:45
02/23/17
17:45
Hot Stocks
CBOE Holdings to repplace Pitney Bowes in S&P 500 as of 3/1 open »

CBOE (CBOE) is acquiring…

CBOE

CBOE Holdings

$80.26

-0.28 (-0.35%)

PBI

Pitney Bowes

$13.81

-0.02 (-0.14%)

BATS

Bats Global Markets

$35.65

-0.08 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

INCY

Incyte

$121.95

0.59 (0.49%)

, SE

Spectra Energy

$41.00

-0.31 (-0.75%)

17:42
02/23/17
02/23
17:42
02/23/17
17:42
Hot Stocks
Incyte to replace Spectra Energy in S&P 500 as of 2/28 open »

Spectra Energy (SE) is…

INCY

Incyte

$121.95

0.59 (0.49%)

SE

Spectra Energy

$41.00

-0.31 (-0.75%)

ENB

Enbridge

$41.71

-0.44 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 06

    Mar

  • 14

    Mar

  • 01

    Apr

  • 19

    Apr

STMP

Stamps.com

$133.75

-0.7 (-0.52%)

17:41
02/23/17
02/23
17:41
02/23/17
17:41
Earnings
Stamps.com reports Q4 EPS $2.73, consensus $2.36 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$121.95

0.59 (0.49%)

, CBOE

CBOE Holdings

$80.26

-0.28 (-0.35%)

17:39
02/23/17
02/23
17:39
02/23/17
17:39
Hot Stocks
Breaking Hot Stocks news story on Incyte, CBOE Holdings, Regency Centers »

Incyte, CBOE Holdings,…

INCY

Incyte

$121.95

0.59 (0.49%)

CBOE

CBOE Holdings

$80.26

-0.28 (-0.35%)

REG

Regency Centers

$70.95

0.94 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

  • 14

    Mar

  • 01

    Apr

  • 19

    Apr

MTZ

MasTec

$37.05

-0.45 (-1.20%)

17:36
02/23/17
02/23
17:36
02/23/17
17:36
Earnings
MasTec sees Q1 adjusted EPS 51c, consensus 23c »

Sees Q1 revenue $1.05B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

MTZ

MasTec

$37.05

-0.45 (-1.20%)

17:36
02/23/17
02/23
17:36
02/23/17
17:36
Earnings
MasTec sees FY17 adjusted EPS $2.35, consensus $2.09 »

Sees FY17 revenue $5.5B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

GOOG

Alphabet

$831.33

0.57 (0.07%)

, GOOGL

Alphabet Class A

$851.00

-0.36 (-0.04%)

17:35
02/23/17
02/23
17:35
02/23/17
17:35
Periodicals
Breaking Periodicals news story on Alphabet, Alphabet Class A »

Alphabet's Waymo…

GOOG

Alphabet

$831.33

0.57 (0.07%)

GOOGL

Alphabet Class A

$851.00

-0.36 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 06

    Mar

  • 19

    Mar

MTZ

MasTec

$37.05

-0.45 (-1.20%)

17:34
02/23/17
02/23
17:34
02/23/17
17:34
Earnings
MasTec reports Q4 adjusted EPS 70c, consensus 54c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

SSRI

Silver Standard

$10.90

-0.06 (-0.55%)

17:34
02/23/17
02/23
17:34
02/23/17
17:34
Earnings
Silver Standard reports Q4 adjusted EPS 26c, consensus 18c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

ALJ

Alon USA Energy

$11.73

0.17 (1.47%)

17:34
02/23/17
02/23
17:34
02/23/17
17:34
Earnings
Alon USA Energy reports Q4 EPS ex-items (20c), consensus (33c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.